Media - Merck.com
Merck's online newsroom offers real-time news about Merck's prescription medicines, vaccines and consumer care products.
News releases - Merck.com
Oct 28, 2024 · Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers. October 23, 2024. CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older. October 19, 2024.
Media library & contacts - Merck.com
Receive company news, updates and other information. Merck's library of assets, photography, video, and contacts for media professionals.
Company fact sheet - Merck.com
Dec 31, 2023 · Merck is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. View the list of products marketed in the U.S.
Merck | Home
Customize my Settings. At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
Discover Job Opportunities at Merck | Merck Careers
Explore current job opportunities at Merck. Learn more about careers in Business Support, Clinical, Engineering, Information Technology, Research & Development, Manufacturing and Marketing.
Contact us - Merck.com
Global media relations: Phone: +1 908-740-5633. Email: mediarelations@merck.com. Not a member of the media? We want to make sure you find the information you need. Members of global media relations may only answer calls and emails from journalists.
Merck Strengthens Immunology Pipeline with Acquisition of …
Apr 16, 2023 · Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. Save. April 16, 2023 6:00 am ET. PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions. Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in ...
Merck to Acquire Caraway Therapeutics, Inc. - Merck.com
Nov 21, 2023 · Merck to Acquire Caraway Therapeutics, Inc. Save. November 21, 2023 6:45 am ET. Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases. RAHWAY, N.J., & CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc ...
Merck to Acquire Harpoon Therapeutics, Further Diversifying …
Jan 8, 2024 · Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline. Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors.